Vázquez‑Morales E, Verdugo‑Meza RA, Godínez‑Alvarado M, Chávez‑Covarrubias G

Language: Spanish
References: 10
Page: 166-168
PDF size: 143.91 Kb.

ABSTRACT

Introduction: OA is currently the fifth leading cause of adult disability, its prevalence increases from age 40. Viscosupplementation is a treatment for the early stages of knee OA. Objective: To compare efficacy and quality of life in patients with symptomatic gonartrosis, treated with high and low molecular weight hyaluronic acid. Material and methods: Analytical, retrospective, cross-sectional, observational study of clinical records of patients diagnosed with grade II and grade III gonarthrosis, October 2017 to June 2018, treated with viscosupplementation with high molecular weight hyaluronic acid or low molecular weight; WOMAC quality of life and scale were analyzed prior to the first application and tracked at two, four and six months. Results: 194 patients, aged between 30 to 87 years (promedio 61.85; SD = 11.3); 134 women (69.1%), 60 men (30.9%). In both groups the evolution was towards improvement, with a decrease in the WOMAC score, with no significant difference between groups. The WOMAC score had a minimum increase after 6 months of application in both groups, which is interpreted as decreasing the therapeutic effect. Two patients had localized minimal adverse reactions which were resolved with general measures. Conclusion: Hyaluronic acid in both presentations, high and low molecular weight, are effective in the treatment of symptomatic goonarthrosis without difference to molecular weight.

REFERENCES

1. Dasa V, DeKoven M, Sun K, Scott A, Lim S. Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database. Drugs Context. 2016; 5: 212296.

2. Telikicherla M, Kamath SU. Accuracy of needle placement into the intra-articular space of the knee in osteoarthritis patients for viscosupplementation. J Clin Diagn Res. 2016; 10(2): RC15-7.

3. Tammachote N, Kanitnate S, Yakumpor T, Panichkul P. Intra-articular, single-shot hylan G-F 20 hyaluronic acid injection compared with corticosteroid in knee osteoarthritis: a double-blind, randomized controlled trial. J Bone Joint Surg Am. 2016; 98(11): 885-92.

4. Sadabad HN, Behzadifar M, Arasteh F, Behzadifar M, Dehghan HR. Efficacy of platelet-rich plasma versus hyaluronic acid for treatment of knee osteoarthritis: a systematic review and meta-analysis. Electron Physician. 2016; 8(3): 2115-22.

5. Cooper C, Rannou F, Richette P, Bruyčre O, Al-Daghri N, Altman RD, et al. Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Arthritis Care Res (Hoboken). 2017; 69(9): 1287-96.

6. Sun SF, Hsu CW, Lin HS, Liou IH, Chen YH, Hung CL. Comparison of single intra-articular injection of novel hyaluronan (HYA-JOINT Plus) with Synvisc-One for knee osteoarthritis: a randomized, controlled, double-blind trial of efficacy and safety. J Bone Joint Surg Am. 2017; 99(6): 462-71.

7. Dai WL, Lin ZM, Guo DH, Shi ZJ, Wang J. Efficacy and safety of Hylan versus hyaluronic acid in the treatment of knee osteoarthritis. J Knee Surg. 2019; 32(3): 259-68.

8. Lee JK, Lee BY, Shin WY, An MJ, Jung KI, Yoon SR. In reply: comment on «effect of extracorporeal shockwave therapy versus intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis. Ann Rehabil Med. 2018; 42(2): 374.

9. Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, et al. Single, intra-articular treatment with 6 ml Hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010; 69(1): 113-9.

10. Vitanzo PC Jr, Sennett BJ. Hyaluronans: is clinical effectiveness dependent on molecular weight? Am J Orthop (Belle Mead NJ). 2006; 35(9): 421-8.